Start › Rak prostaty › Illinois › Chicago
Badania kliniczne dla Rak prostaty w mieście Chicago, IL
45 badań dla Rak prostaty szuka uczestników w ośrodkach w mieście Chicago i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RekrutacjaFaza 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RekrutacjaFaza 3
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- University of Chicago Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- i 1 więcej
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 2
- University of Illinois Cancer Center, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekrutacjaFaza 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
RekrutacjaFaza 2/3
- University of Chicago, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekrutacjaFaza 3
- University of Illinois Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RekrutacjaFaza 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
RekrutacjaFaza 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RekrutacjaFaza 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RekrutacjaFaza 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RekrutacjaFaza 1
- University of Illinois Hospital & Health Sciences System, Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Rekrutacja
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RekrutacjaFaza 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
RekrutacjaFaza 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
RekrutacjaFaza 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RekrutacjaFaza 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RekrutacjaFaza 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekrutacjaFaza 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
RekrutacjaFaza 3Zapraszamy zdrowych ochotników
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RekrutacjaFaza 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekrutacjaFaza 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
RekrutacjaFaza 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RekrutacjaWczesna faza 1Zapraszamy zdrowych ochotników
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
RekrutacjaFaza 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
RekrutacjaBadanie obserwacyjne
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
RekrutacjaFaza 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
RekrutacjaFaza 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
Rekrutacja
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
RekrutacjaFaza 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekrutacjaFaza 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Rekrutacja
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
RekrutacjaFaza 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
Rekrutacja
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekrutacjaFaza 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
RekrutacjaBadanie obserwacyjne
- The University of Chicago, Hyde Park · 5 mi dalej
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RekrutacjaFaza 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekrutacjaFaza 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Rekrutacja
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RekrutacjaFaza 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
RekrutacjaBadanie obserwacyjne
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RekrutacjaFaza 4
- University of Chicago Medical Center, Chicago
Badania dla Rak prostaty w innych miastach
- New York City, NY103 badań
- Houston, TX76 badań
- Los Angeles, CA61 badań
- Boston, MA59 badań
- St. Louis, MO46 badań
- San Francisco, CA45 badań
- Philadelphia, PA44 badań
- Baltimore, MD43 badań
- Nashville, TN42 badań
- Seattle, WA42 badań
- Washington, DC38 badań
- Dallas, TX36 badań
Inne badania w mieście Chicago
- Niedrobnokomórkowy rak płuca61 badań
- Rak piersi58 badań
- Nowotwory (wszystkie typy)51 badań
- Nowotwór przerzutowy45 badań
- Otyłość41 badań
- Rak płuc41 badań
- Rak jajnika36 badań
- Udar34 badań
- Rak jelita grubego i odbytnicy33 badań
- Niewydolność serca31 badań
- Nadwaga28 badań
- Rak płaskonabłonkowy głowy i szyi26 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.